No Data
No Data
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $9 Price Target
Allogene Receives FDA RMAT Designation for Its Metastatic Renal Cell Carcinoma Treatment
Express News | Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Allo-316, an Allocar T™ Investigational Product for Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (Rcc)
Express News | Artiva Biotherapeutics Appoints Alison Moore, Ph.d., to Its Board of Directors
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
No Data
No Data